drugset
drugset / Trial / NCT02211872

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

NCT02211872 ↗

Phase 1 Completed 63 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study was to determine the maximum tolerated dose (MTD) of BI 2536 BS in patients with advanced solid tumours. Secondary objectives were the evaluation of safety, efficacy, and pharmacokinetics of BI 2536 BS

Timeline

Start
2004-08
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 2536 BS Unknown — Intravenous

Indications

neoplasm